QQQ   431.49 (+0.10%)
AAPL   169.74 (-1.71%)
MSFT   417.06 (+0.83%)
META   502.47 (+0.45%)
GOOGL   155.28 (+0.27%)
AMZN   183.99 (+0.20%)
TSLA   156.71 (-2.95%)
NVDA   878.21 (+2.12%)
AMD   163.79 (+2.16%)
NIO   3.88 (-0.26%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.85 (+0.40%)
GE   156.46 (+1.80%)
CGC   6.84 (-2.01%)
DIS   114.11 (+1.03%)
AMC   2.78 (+12.55%)
PFE   25.83 (-0.31%)
PYPL   63.90 (+0.61%)
XOM   118.91 (-0.64%)
QQQ   431.49 (+0.10%)
AAPL   169.74 (-1.71%)
MSFT   417.06 (+0.83%)
META   502.47 (+0.45%)
GOOGL   155.28 (+0.27%)
AMZN   183.99 (+0.20%)
TSLA   156.71 (-2.95%)
NVDA   878.21 (+2.12%)
AMD   163.79 (+2.16%)
NIO   3.88 (-0.26%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.85 (+0.40%)
GE   156.46 (+1.80%)
CGC   6.84 (-2.01%)
DIS   114.11 (+1.03%)
AMC   2.78 (+12.55%)
PFE   25.83 (-0.31%)
PYPL   63.90 (+0.61%)
XOM   118.91 (-0.64%)
QQQ   431.49 (+0.10%)
AAPL   169.74 (-1.71%)
MSFT   417.06 (+0.83%)
META   502.47 (+0.45%)
GOOGL   155.28 (+0.27%)
AMZN   183.99 (+0.20%)
TSLA   156.71 (-2.95%)
NVDA   878.21 (+2.12%)
AMD   163.79 (+2.16%)
NIO   3.88 (-0.26%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.85 (+0.40%)
GE   156.46 (+1.80%)
CGC   6.84 (-2.01%)
DIS   114.11 (+1.03%)
AMC   2.78 (+12.55%)
PFE   25.83 (-0.31%)
PYPL   63.90 (+0.61%)
XOM   118.91 (-0.64%)
QQQ   431.49 (+0.10%)
AAPL   169.74 (-1.71%)
MSFT   417.06 (+0.83%)
META   502.47 (+0.45%)
GOOGL   155.28 (+0.27%)
AMZN   183.99 (+0.20%)
TSLA   156.71 (-2.95%)
NVDA   878.21 (+2.12%)
AMD   163.79 (+2.16%)
NIO   3.88 (-0.26%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.85 (+0.40%)
GE   156.46 (+1.80%)
CGC   6.84 (-2.01%)
DIS   114.11 (+1.03%)
AMC   2.78 (+12.55%)
PFE   25.83 (-0.31%)
PYPL   63.90 (+0.61%)
XOM   118.91 (-0.64%)
Free Trial
TSE:TR

Trillium Therapeutics (TR) Stock Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)
Free TR Stock Alerts
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
49,075 shs
Average Volume
99,071 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
TR stock logo

About Trillium Therapeutics Stock (TSE:TR)

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.

TR Stock News Headlines

April 15, 2024 | finance.yahoo.com
Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio
April 2, 2024 | finance.yahoo.com
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
April 16, 2024 | The Bull Report (Ad)
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
March 12, 2024 | finance.yahoo.com
Ratio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted Radiopharmaceuticals
January 17, 2024 | bizjournals.com
Ratio Therapeutics raises $50M for tumor-targeting radiopharmaceuticals
June 22, 2023 | finance.yahoo.com
Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor
June 20, 2023 | benzinga.com
PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight
May 9, 2023 | finance.yahoo.com
Ratio Therapeutics Announces Opening of New Research and Development Facility
April 16, 2024 | The Bull Report (Ad)
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
April 25, 2023 | finance.yahoo.com
Trillium Engineering Announces Its Latest Innovation in Cameras Utilizing AI Technology - HD80-AIM
March 10, 2023 | msn.com
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
February 6, 2023 | finanznachrichten.de
Viridian Therapeutics, Inc: Viridian Appoints Scott Myers as President and Chief Executive Officer
January 28, 2023 | detroitnews.com
Taylor Trillium building into Division 4 state power, behind coach Terrell George
December 19, 2022 | benzinga.com
Leiomyosarcoma Drug Pipeline Research Report 2022: Comprehensive Insights on 18+ Companies and 18+ Pipeline Drugs
December 6, 2022 | finance.yahoo.com
Ratio Therapeutics Appoints Reed Malleck as Chief Financial Officer
November 3, 2022 | seekingalpha.com
Pfizer: Q3 Earnings Review - Planning For Life After COVID
August 8, 2022 | msn.com
Cash-rich Pfizer snaps up Global Blood Therapeutics for $5.4 billion
May 22, 2022 | seekingalpha.com
Pfizer: Management's M&A Activity Is Winning Me Over
May 18, 2022 | finanznachrichten.de
Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102
May 18, 2022 | stockhouse.com
Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102
May 14, 2022 | msn.com
3 Dirt-Cheap Stocks You Can Buy Right Now
May 10, 2022 | baystreet.ca
Pfizer Buys Biohaven for $11.6B
February 17, 2022 | morningstar.com
NeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, Ontario
January 25, 2022 | yahoo.com
$51,300 OTF Grant helped breast cancer patients in Ontario access educational resources during the pandemic
January 12, 2022 | finance.yahoo.com
TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer
December 20, 2021 | apnews.com
Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director
November 17, 2021 | law360.com
Pfizer's $2.3B Trillium Deal Closes Without FTC Challenge
See More Headlines
Receive TR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
TSE:TR
CUSIP
N/A
CIK
N/A
Web
www.trilliumtherapeutics.com
Phone
+1-416-5950627
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Calvin R. Stiller M.D.
    Independent Chairman of the Board
  • Niclas Stiernholm
    President, Chief Executive Officer, Director
  • James T. Parsons
    Chief Financial Officer
  • Malik Slassi
    Senior Vice President - Discovery Research
  • Robert Uger
    Chief Scientific Officer
  • Scott Duncan
    Director of Intellectual Property
  • Penka Petrova
    Chief Development Officer
  • Eric L Sievers
    Chief Medical Officer
  • Luke M. Beshar CPA (Age 59)
    Independent Director
  • Henry Friesen M.D. (Age 79)
    Independent Director

TR Stock Analysis - Frequently Asked Questions

Is Trillium Therapeutics a good dividend stock?

Trillium Therapeutics (TSE:TR) pays an annual dividend of C$0.36 per share and currently has a dividend yield of 0.00%.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Cedar Fair (FUN), Trillium Therapeutics (TRIL), Ford Motor (F), Express Scripts (ESRX), Esperion Therapeutics (ESPR), ConocoPhillips (COP), Canadian Natural Resources (CNQ), bluebird bio (BLUE) and Biogen (BIIB).

How do I buy shares of Trillium Therapeutics?

Shares of TR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:TR) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Your eBook: Mastering Earnings Announcements Trading
StockEarnings
The only accurate crypto trading system I know …
Weiss Ratings
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
1970’s computer coder issues shocking A.I. warning
TradeSmith